|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 232.56 USD | +0.06% |
|
-7.89% | -3.30% |
| 03-11 | Resmed Insider Sold Shares Worth $1,252,902, According to a Recent SEC Filing | MT |
| 03-11 | Baird Adjusts Price Target on ResMed to $272 From $281, Maintains Neutral Rating | MT |
Evolution of the Average Target: ResMed, Inc.
Evolution of the Target Price: ResMed, Inc.
Changes in Analyst Recommendations: ResMed, Inc.
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +27.73% | |||||
| +39.52% | |||||
| +27.24% | |||||
| +42.23% | |||||
| +51.45% | |||||
| +42% | |||||
| +14.01% | |||||
| +32.3% | |||||
| +46.28% | |||||
| +54.68% | |||||
| Average | +37.74% | |||||
| Weighted average by Cap. | +37.55% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Baird | |
| Morgans Financial | |
| Piper Sandler | |
| RBC Capital Markets | |
| Wolfe Research | |
| Wells Fargo Securities | |
| KeyBanc Capital Markets | |
| Stifel Nicolaus | |
| Jefferies & Co. | |
| Citigroup | |
| Morgan Stanley | |
| Mizuho Securities | |
| CICC Research | |
| JPMorgan Chase | |
| UBS | |
| Jarden Research | |
| Oppenheimer | |
| Needham & Co. | |
| Evans & Partners | |
| BofA Securities | |
| JMP Securities | |
| Goldman Sachs | |
| Macquarie | |
| J.P. Morgan Chase |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- RMD Stock
- Consensus ResMed, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition